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Screeninga b s t r a c t
In the absence of good animal models, Controlled Human Infection Models (CHIMs) are useful to assess
efficacy of new vaccine candidates against Enterotoxic Escherichia coli (ETEC), as well as other preventive
or therapeutic interventions. At the 2018 Vaccines Against Shigella and ETEC (VASE) conference, a work-
shop was held to further review and discuss new challenge model developments and key issues related to
further model standardization. During the workshop, invited speakers briefly summarized for attendees
recent developments and main agenda issues before workshop participants were divided into four groups
for more focused discussions.
The main issues discussed were: (1) whether there is a need for more ETEC strains to test a diversity of
vaccine candidates, and if so, what criteria/qualities are desirable in strain selection; (2) how ETEC CHIMs
could be more standardized to better support ETEC vaccine development; (3) how volunteer selection cri-
teria and screening should be performed, and; (4) how an expanded sample collection schema and col-
laborative analysis plan may facilitate a more in-depth assessment of the role of antigen-specific humoral
and cellular immune responses in ETEC infection, and provide better insights into ETEC pathogenesis and
correlates of protection.
The workshop concluded that additional challenge strains may need to be developed to better support
new vaccines and therapeutics that are advancing in the development pipeline. In this regard, the need
for a well characterized ST-only expressing ETEC strain was highlighted as a priority given that promising
new heat stable toxoid based vaccine candidates are on the horizon. In addition, further standardization
of the ETEC CHIMs was strongly encouraged, noting that it may not be realistic to standardize across all
strains. Also, intensified volunteer screening may result in higher attack rates, although more stringent
eligibility criteria may contribute to a more limited application of the model and diminish its represen-
tativeness. Finally, a sampling schedule and priority list for minimum set of samples was also proposed.
Future workshops could be held to further refine standards for ETEC CHIMS and to facilitate more collab-
orative work on stored sample sets from previous and future ETEC CHIMs to maximize the contribution of
these trials to our understanding of ETEC pathogenesis and our development of better prevention and
control measures for this important pathogen.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Background
Controlled human infection models (CHIMs) have been devel-
oped as an important tool to assess preliminary efficacy of proto-
type vaccine candidates for several intestinal pathogens,
including norovirus, V. cholerae, Shigella, Campylobacter and entero-toxigenic Escherichia coli (ETEC). CHIMs have the potential to speed
up selection of promising vaccine candidates at a lower cost than
field trials. It is also increasingly appreciated that CHIMs can be
utilized to expand our knowledge of disease pathogenesis and cor-
relates of protection. The VASE (Vaccines Against Shigella and
ETEC) 2018 workshop followed up on central topics raised in the
2016 VASE CHIM workshop [1,2] with a specific focus on the ETEC
model and new data obtained and analysed over the past two
years. In particular, although the ETEC CHIM has been used suc-
cessfully to evaluate vaccine candidates [3–10], there may be
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include inoculum preparation, sample testing and clinical outcome
assessment [11]. This need is highlighted by inconsistent attack
rates in several trials [6,12]. Potentially, enhanced screening to
exclude individuals resistant to infection may help increase the
likelihood of achieving a sufficiently high attack rate among pur-
ported naïve individuals [6]. Additionally, we wanted to explore
whether new ETEC strains should be developed into challenge
strains and used to evaluate ETEC vaccines or treatment alterna-
tives. This workshop brought together a group of researchers with
various perspectives and experiences to discuss these issues. This
summary article thus reflects the current views of a rapidly evolv-
ing landscape related to further development and utilization of
ETEC CHIMs.2. Methods
After a short introduction, this two-hour workshop started with
four 10-minute introductions to address four key issues pertaining
to ETEC controlled human infection models;
1. Is there a need for more ETEC challenge strains, and if so, what
criteria/qualities are desirable in strain selection?
2. What is the rationale for evaluating host susceptibility to ETEC
and how such data may be used to refine subject selection cri-
teria while ensuring a representative study population?
3. How could ETEC CHIMs be more standardized to better support
ETEC vaccine development, incorporating novel methods of
inoculum preparation, recent experience in dose responses,
fasting times, and the evaluation of clinical outcomes?
4. How can we improve sample collection schemes and collabora-
tive analysis that facilitate more in-depth assessment of host
responses to ETEC infection and provide better insights into
how ETEC vaccine candidates may impact on both acute and
potentially more long-term consequences of ETEC infections?
After short presentations of these issues, participants were allo-
cated to four different groups, each discussing issues related to one
of the four presented topics for 40 min. Groups were moderated by
the topic presenter. Group discussions were then summarised and
discussed in a 35 min’ plenary session.3. Results and discussion
3.1. Strain selection
The challenge strains are a principal component in ETEC CHIM
studies. The characteristics of each strain should be driven by a
clearly defined purpose for the challenge study; most of the time,
the purpose is for testing vaccines or therapeutics with specific
mechanisms of action so strain-specific CHIMs are an important
consideration. Strains expressing the most common CFs are often
selected as relevant strains, but it could also be important to con-
sider whether the strain expresses those CFs to a certain minimal
level in vivo or in association with intestinal epithelial cell
in vitro [13–15]. In some cases it could be relevant to conduct ‘con-
firmatory challenge studies’ to test the effect of a vaccine/thera-
peutic with two different strains.
A comprehensive review of strains used was made in 2011 [12].
A few more strains have since been published, so that now 14 dif-
ferent ETEC strains have been tested in at least one human trial
(Table 1). ETEC CHIMs have historically been used to better define
the parameters of ETEC pathogenesis and immunity and have more
recently become a platform for the evaluation of new active or pas-
sive interventions for prevention of ETEC as well as new therapeu-tics for ETEC. Immunological protection against different ETEC
strains is dependent upon many factors, including the strain’s toxin
profile (production of the heat-labile (LT) and/or heat-stable
enterotoxins (ST)) and expression of colonization factors (CF) and
lipopolysaccharide (LPS) O-antigens. Desired characteristics of
ETEC challenge strains may vary according to the purpose of the
study. For example, to test a new drug to treat or prevent diarrhea,
one may use any strain that effectively causes diarrhea, such as
H10407. The group touched upon the importance of selecting a
strain from an adult or pediatric diarrhea case to optimize the like-
lihood for successful testing of a particular vaccine. For a vaccine
intended for children in low and middle income countries (LMICs),
one would want to test its efficacy against strains that are common
causes of diarrhea in these settings. The choice would then be an
ST-expressing ETEC strain, preferably also expressing CFA/I or
CS6. If testing killed whole cell or live oral ETEC vaccines one
may want to avoid the O- and H-antigens of the vaccine candidates
to rule out their contribution to strain-specific immunity. It is on
this backdrop that the potential value of new ETEC strains is high-
lighted. For example, an ETEC strain only expressing ST would be of
value in assessing the efficacy of an ST-toxoid based vaccine by
avoiding the influence of LT. With an ST only expressing ETEC
strain, one could also test the contribution of LT-specific immunity,
when using dmLT as an adjuvant to other non-LT vaccine compo-
nents such as the CFs or CF subunits. There was a consensus that
CHIMs are not a substitute for field trials or a way to avoid them.
The challenge strain should be fully susceptible to multiple oral
antibiotics (current frontline treatment is ciprofloxacin) to facili-
tate the treatment of volunteers after challenge. The group advo-
cated for strain sequencing, as it offers even more strain-specific
information that could prove valuable for not only regulators, but
also to provide insight into other parameters (such as safety,
antibiotic resistance, antigen discovery, etc). Through whole geno-
mic sequencing, bioinformatics analysis has identified previously
undescribed CF loci from ETEC strains that were thought to be
CF-negative based on previous methods [16]. Also, through whole
genome sequencing, temperate bacteriophages, which could theo-
retically confer antibiotic resistance, could be identified [17].
Researchers involved in CHIMs should be aware that phage testing
may have implications for consistent challenge strain production.
In the US, GMP manufacturers must not introduce phages into
their facilities, so regulators often ask for GMP lots that undergo
phage testing. The group agreed that this warrants further
discussion.
Using new ETEC strains in CHIMs may be more complicated
than using strains already used in humans, since the regulatory
landscape for these strains is in transition. The U.S. FDA, strongly
recommends challenge agent(s) to be registered under Investiga-
tional New Drug application (IND) and Good Manufacturing Prac-
tice (GMP). The Medicines and Healthcare products Regulatory
Agency (MHRA) in the UK and the European Medicines Agency
(EMA) do not review or approve human challenge study protocols,
but they are considered a Non-Investigational Medicinal Product
(NIMP) and do require GMP.
3.2. Host susceptibility and volunteer selection
Parameters known to affect host susceptibility include pre-
existing immunity, genetic susceptibility, the microbiome, nutri-
tional status, and intestinal mucosal integrity [18–20]. In CHIMs
there is already an extensive screen of potential volunteers to
address concerns of safety, ethics, results interpretability and prac-
tical issues. Currently, ETEC CHIM studies are designed with the
intent to carefully select individuals that are healthy, immunocom-
petent, and have good nutritional status and intestinal mucosal
integrity. Yet, the selection of volunteers by even more criteria
Table 1
ETEC strains used in controlled human infection models.
Strain Toxin Colonization Factor(s) Serogroup (if known) Comment Ref.
H10407 STh, STp, LT CFA/I O78:H11 Most commonly used [37]
H10407p Deleted CFA/I 0 of 9 with diarrhea at 109 cfu (1979) [38]
B7A STh, LT CS6, CS21* O148:H48 Second most commonly used [39]
E24377A STh, LT CS1, CS3 O139:H28 Third most commonly used [6]
214-4 STp only CS6 O167:H5 (1976–1981), >70% diarrhea at 108 cfu [40]
B2C LT, ST CS2, CS3 O6:H16 single study (1971) [39]
E2528-C1 LT CS8, CS14 O25:NM (1977–79), 40% diarrhea at 109 cfu [41]
TD225-C4 LT unknown O75:H9 (1977–81), >50% diarrhea with 108 cfu [42]
H1765 LT, ST CFA/II O6:H16 single study (1984) [43]
LSN03-016011/A LT CS17 O8:H- Two studies done, plus one still blinded [44]
WS0115A LT, STp CS19 O114:H- single study (2011) [44]
DS26-1 LT CS19 O8:H9 single study (2011), no diarrhea with 108 cfu [44]
TW10598 STh, LT CS2, CS3, CS21* O6:H16 single study (2014) [45]
TW10722 STh only CS5, CS6 O115:H5 >70% with diarrhea at 1010 cfu Sakkestad et al. manuscript
TW11681 STh only CFA/I, CS21* O19:H45 Non-diarrheal symptoms 106–108 cfu Sakkestad et al. in revision
* Other strains may also express CS21, but may not be tested for this.
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In CHIMs with other bacterial enteropathogens immunologic
screening parameters have been included as part of eligibility cri-
teria; however, this has not been incorporated in ETEC CHIMs.
Pre-existing pathogen-specific or cross-reactive antibodies
could abrogate the diarrheal illness elicited during an ETEC chal-
lenge. It is evident from field studies that serum titers of antibodies
affects risk for acquiring diarrhea in travellers [18]. A less clear, but
similar trend has been shown for the effect of anti CFA/I titers
against ETEC disease in a pediatric population in Egypt [21], and
anti-CS3 IgA was significantly associated with less moderate to
severe diarrhea in an ETEC E24377A model [6]. However, no asso-
ciation was found with anti CS3-IgG nor anti-LT IgG or IgA. More
limited studies looking at T cell immunity in ETEC CHIMs suggests
a potential role for T follicular helper cells in the risk of diarrhea
[22,23].
Going beyond colonization factors and toxins, the ETEC protein
microarray may be used to reveal immune responses towards
pathovar-specific secreted proteins like EtpA and EatA, as well as
the conserved E. coli antigens YghJ, FliC [24]. The method has also
identified novel antibodies against proteins included on the array
that seemingly correlate with disease severity following challenge
with ETEC strain B7A (unpublished data).
For some pathogens the expression of certain host factors is
known to increase the risk of severity of infection, such as blood
group O with V. cholerae and FUT2 secretor status with noroviruses.
Blood group seem to play a role for development of some ETEC dis-
ease. It has been shown that blood group A human volunteers chal-
lenged with ETEC H10407 developed severe diarrhea more
frequently than volunteers with other blood groups [20]. Children
with Le(a+b) blood type had significantly higher incidence of diar-
rhea caused by strains with CFA/I group fimbriae than Le(ab+)
[25]. Thiswas not found in ETEC expressing CS6 [26], indicating that
this difference might be strain specific. Microbiome data point to
potential differences in some bacterial populations between symp-
tomatic and asymptomatic volunteers challenged with H10407
[19]. Unpublished data were presented that highlight similar differ-
ences in those meeting clinical endpoints following B7A CHIM.
Based on the above, volunteers could be selected on several
more criteria including: ABO blood group, potential genetic sus-
ceptibility markers, absence of protective microbiome, immuno-
suppression, immunologic screening to enroll only subjects able
to mount a vaccine response (based on titers to commonly admin-
istered vaccines), pre-existing immunity to ETEC specific antigens,
IgA deficiency and previous travel in ETEC endemic countries.
It is presumed that the randomized nature of ETEC vaccine
CHIM studies would equally distribute volunteers with variablesusceptibilities. The obvious value of doing rigorous screening is
to select persons that are more likely to be susceptible to illness
in both groups, so that the intervention is the most important fac-
tor determining protection against illness. With stricter selection
criteria one could remove a set of potential or known confounders
and effect modifiers. This may help minimize sample size, and
thereby also cost and arguably it would be more ethically prudent;
however, one must not dismiss the logistic challenges and cost of
increased screening.
The major concern with more extensive screening is that the
screened population might not be representative of the final target
population. Also, there may be strain-specific criteria that can be
problematic to generalise, and defining a new set of inclusion cri-
teria may require the model to be re-validated. However, expanded
screening might be appropriate for small studies with limited sam-
ple size to answer specific questions early in a vaccine develop-
ment phase. Another option could be stratified randomization in
which these parameters are utilized to construct strata and a ran-
domization scheme is performed separately within each stratum;
however, most agreed that the strata-specific criteria are not suffi-
ciently clear to incorporate this as a standardized strategy. Ulti-
mately, stratified analyses and defining some of these metrics a
priori may be a better alternative to extensive screening.
A side issue discussed was whether increased susceptibility of
volunteers could be achieved by setting dietary restrictions during
CHIM. It was speculated whether attack rates might increase if
yogurt or other probiotics were not allowed on the ward, and that
a vegetarian diet would better mimic the situation of a developing
country child.3.3. Standardization of ETEC CHIMs
The inoculum preparation is an important aspect of potential
model variability. While the overwhelming majority of studies
have been performed using freshly harvested cells from plate
grown inocula, at least one experiment with a frozen bulk lot has
been done [22]. In further efforts to standardize ETEC inoculum
for ETEC CHIMs, a lyophilized B7A challenge strain has been pro-
duced under cGMP by PATH with BMGF support, but it has yet to
be evaluated in human volunteers (R. Walker, EVI PATH personal
communication). The inoculum is currently given with bicarbonate
solution before and with the challenge dose, while previously it has
been given with milk or with saline. The use of the bicarbonate
buffer as the vehicle of delivery has improved the previously
observed wide variability in attack rates of challenges and likely
is due to better neutralization of gastric acid.
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tative of natural infection However, one also needs to give a dose
that causes reproducible attack rates of diarrheal disease. Model
refinement trials have been done using H10407 given with bicar-
bonate or CeraVacx buffers at doses between 10^5 and 10^8 focus-
ing on incorporating an overnight fast [11,27]. Similarly, studies
with strain B7A compared an overnight and 90 min pre-challenge
fast at doses 10^8 to 10^10 [28]. Inoculum preparation and dosing
should be standardized and shared across sites. Lyophilized prepa-
rations might be attractive from a regulatory perspective, as there
would be release criteria associated with vialed product rather
than GMP regulations only around cell banks. However, one impor-
tant concern regarding lyophilized products is the consistency of
live/dead bacteria ratio. One of the uncertainties with agar grown
inocula is a potential contribution of preformed ST or LT on volun-
teer symptoms. Presently some sites wash their inocula to avoid
this, but some do not. The disease profile in studies using washed
and non-washed inoculum appear to be similar, but there are no
studies directly comparing the twomethods. The question was also
raised whether the model of one large bolus of ETEC now used in
CHIMS really reflect natural infection in children, where a child
most probably is repeatedly exposed to variable, smaller inocula
of ETEC (which would be harder to replicate in a challenge model).
An attack rate of 60–70% is commonly used as a target in
CHIMs. The reasoning behind this attack rate is to avoid over-
whelming, and thereby underestimating, a normally protective
vaccine immune response [11]. Inocula of each pathogen should
therefore be kept as low as possible to achieve this attack rate tar-
get. It would benefit and help standardize sample size calculations
for ETEC CHIMs to explicitly agree and accept a target attack rate.
Reproducibility of naïve attack rates have been tested in three
cohorts receiving 10^7 cfu of H10407 [10]. There is a need for
reproducible, well-defined endpoints where one may assess the
severity of stool output based on weight of grade-3-5 diarrheal
stools and/or by the frequency of passing diarrheic stools during
a pre-set time frame following challenges and also account for
associated symptoms like abdominal discomfort and fever. Instead,
most commonly, the primary endpoints for ETEC CHIM have
focused only on stool frequency and/or volume [12]. An alternative
endpoint has recently been proposed based on a disease severity
score which incorporates stool output with other signs and symp-
toms important for understanding disease severity [29]. Such sec-
ondary symptoms of interest include: maximum 24-h loose stool
output, severe diarrhea, diarrhea of any severity, total loose stool
output, moderate to severe gastrointestinal symptoms like nausea,
fever, vomiting, anorexia, abdominal pain/cramps, time to onset of
diarrhea, percent with moderate to severe ETEC illness, and quan-
titative stool culture (cfu/gram stool). A disease severity score
could potentially reduce the sample size required for cohorts
[29]. This is extremely attractive as CHIMs are expensive and inpa-
tient unit availability is limited. Use of the score also allows for
standardization of clinical outcomes across studies using the same
pathogen. It is not clear whether regulatory authorities would
accept a disease score as a composite primary endpoint, but such
a score should automatically be incorporated into CHIM protocols
as a secondary endpoint; eventually one could move to this becom-
ing a primary endpoint for certain target populations.
Clinical outcomes might be affected by the target population.
Studies for vaccines meant for travelers utilize an endpoint focused
on the frequency of stools that might impact functional activity,
whereas for pediatric populations stool volume is more important
due to dehydration implications. It would therefore be important
to standardize those ‘within target population’ clinical endpoints
across models. For example the ACE527-102 trial [7] endpoint
was based on traditional volume/number of stools endpoint, while
the VAC 006 trial (ACE527 ± dmLT) (Harro et al. manuscript inpreparation) endpoint was solely volume, as PATH’s target popula-
tion are children under the age of 5 years.
Standardization can be important and, can be realistically
achievable, with regard to 1. clinical outcomes, 2. inoculum dose
and preparation, and 3. target attack rates. The group agreed that
ETEC CHIMs should be standardized to the extent possible for each
challenge strain and noted that it may not be realistic to standard-
ize across strains nor across pathogens. While the group agreed
standardization to a point is important, there was a noted need
to remain flexible. An advantage of a relatively standardized proto-
col and model across multiple vaccines and multiple sites is that it
gives greater confidence about down-selecting vaccine candidates
and more accurate and realistic comparison of different products/
therapeutics. Standardization may also reduce the need for post-
hoc analysis.3.4. Improve sample collection schemes and collaborative analysis
Given the WHO goal of developing ‘‘a safe, effective and afford-
able ETEC vaccine that reduces moderate to severe diarrheal dis-
ease and morbidity in infants and children under 5 years of age
in LMICs” [30] more can be done to maximize the potential of
CHIMs. Detection of early markers of vaccine safety and efficacy
would be an important tool in bridging the translational research
gap in ETEC vaccine development and possible licensure.
Sample collection, processing and archiving is the cornerstone
of this new translational research and should be funded as part
of the standard budget for ETEC CHIMs. Blood sampling is usually
an important part of every ETEC CHIM to measure immune
responses before and after vaccines and/or experimental infec-
tions. Recent research into a correlate (or even surrogate) of pro-
tection against ETEC has shown interesting associations between
activated circulating T follicular cells (cTfh) and antibody in lym-
phocyte supernatant (ALS) responders to vaccination, as well as a
potential early increase in cTfh in ETEC protected individuals
[22,31]. While blood is generally being centrifuged to obtain
serum/plasma it is often not processed to allow analyses of cellular
immunity or transcriptomics. Often budgets will not allow for the
more laborious sampling protocols necessary to obtain blood ali-
quots with protease inhibitors or RNA stabilizing agents or isola-
tion of peripheral mononuclear cells. Sampling in the first hours
or days after vaccination is seldom done, but may reveal important
early responses to a vaccine or infection that could distinguish sus-
ceptible from resistant, or immune from non-immune, subjects,
such as early levels of intestinal colonization.
For stool sampling, the level of interest is now elevated above
just determining presence/absence of the challenge strain. Samples
could be processed or stored to allow for other analysis such as
qPCR, transcriptomics and microbiome dynamics. A study examin-
ing gut inflammatory responses following infection with C. jejuni
and re-challenge showed the importance of early sampling where
prior infection was shown to blunt inflammation on rechallenge
(Baqar S & Tribble D, personal communication). Increased levels
of myeloperoxidase and calprotectin were found in stool already
in the first day after challenge compared to baseline in subjects
challenged with ETEC B7A (Maciel M, personal communication).
Recent studies also show that symptomatic disease is associated
with increased ETEC shedding [19,27,32,33]. Studies with
H10407 have suggested that a threshold level of shedding
2  107 cfu/gram of stool is associated with a higher likelihood
of developing illness ([19,27,32]. The group discussed the question
and expressed some concern about how aggressive sampling regi-
mens will be tolerated by volunteers during this period. Pilot stud-
ies may be a good way to justify further funding for such sampling.
Some studies have also showed the value of saliva collection as a
Table 2
Proposed tiered sampling plan to standardize and harmonize between ETEC CHIMS, and with Shigella CHIMS.
Tier 1 Priority Immunology Tier 2 Priority Immunology Samples for Banking
Serum IgG/IgA
Fecal IgG/IgA
Antibody in lymphocyte supernatant (ALS)
Antibody secreting cells (ASC)







Other adhesion inhibition assays
ETEC antigen microarrays
Salivary antibodies
Circulating T follicular cells







Proposed sampling plan for future ETEC challenge to test ETEC vaccine candidate in a phase 2b trial.
Tentative Study Events 56 55 53 49 28 27 25 21 1 0 1 2 3 4 5 6 7 8 14 28 56 84 180
Vaccinate and Boost X X
ETEC challenge X
Start Antibiotic Therapy (discharge
after 2–3 neg stools by culture)
X
Stool Culture for ETEC (qPCR –
optional on archived samples.
X X X X X X X X X X X X X X X
Serology LTB, CFs, EtpA, EatA, ST?
IgG/A/M ELISA – B, weekly
X X X X X X X X X X X
ALS / ASC – B, D7 after Vx & D5 after
challenge. No Ag stimulation
X X X X
Memory B & T Cell – B, D28 after Vx
& Challenge (paired with cTfh)
X X X X X
Stool for Fecal IgA/IgG – weekly X X X X X X X X X X X X
Stool for inflammation markers
ELISA – daily, early after challenge
X X X X X X X X X
ALS = Antibody in Lymphocyte Supernatant, ASC = Antibody Secreting Cells B = before, D = day, cTfh = circulating T follicular helper cell.
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is a demanding procedure for both volunteers and staff [35].
Specifically, it was proposed that there should be a focused
effort to collect samples earlier during challenge to assess immune
profiling and transcriptomics (both host and bacterial), intestinal
colonization/shedding and disease risk, intestinal inflammation
and disease severity, microbiome impact on/of infection and
immunization, as well as correlates/surrogates, mechanisms and
mediators of immunity. A systems biology approach to ETEC
CHIMs identified tentative gene activation profiles associated with
reduced susceptibility to ETEC strain H10407 [36]. Early host and
bacterial responses after challenge need further study because of
potential impact on antigen discovery and events that are associ-
ated with reduced colonization and spectrum of illness.
Collecting data on psychomotor vigilance may also prove inter-
esting correlations with diarrheal disease. A recent experiment
showed that decreased psychomotor vigilance coincided with
increased frequency of stool output during Campylobacter chal-
lenge (C. Porter unpublished data).
There are several challenges to expand sample collection and
standardization in CHIMs. Funding for additional sample collec-
tion, processing, testing and archiving can be hard to obtain. In par-
ticular, this is true for further exploration of microbiome effects
and application of more advanced immunological method to help
identify immune correlates and mechanism of protection. There
is also a need for better methods to study colonization. Harmoniza-
tion of sample collection is key to draw as much knowledge from a
well-designed experimental vaccination and/or infection as possi-
ble. This could include standardization of processing of specimens
as well as SOPs for processing and testing of all samples. Sampling
schemes are also dependent on on-site facilities and how enrol-
ment is done. Sampling standardization has been initiated for
Shigella CHIMs and is a good example of a harmonization effortthat should be replicated for ETEC. A tiered sampling plan was sug-
gested for future ETEC vaccine CHIMs (Table 2) to set priorities for
sample collection (Table 3) and harmonization with Shigella
CHIMs. There is a need for a working group to guide harmonization
and consensus on scope, timing and tiered sampling. This group
should work in collaboration with other groups focusing on Shigella
and Campylobacter CHIMs.
4. Conclusion
Overall this workshop resonated enthusiasm for the value of
CHIMs for furthering ETEC vaccine development. There are still
areas that can be refined and one can identify methodological
improvements in every ETEC CHIM performed. Participants were
actively engaged in discussions in all four breakout sessions. It
was believed that through further refinement and standardization,
with expanded sampling regimens, particularly early after chal-
lenge, the full potential of ETEC CHIMs can be realized.
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